TickerFacts.

bioAffinity Technologies, Inc. (BIAF): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$504.8K
Year ended 2025-12-31
$413.1K
Trailing 12 months to 2026-06-30
+267.4%
3-year compound annual growth
$605.6K2021-12-31: $4.8K2022-12-31: $10.2K2023-12-31: $249.6K2024-12-31: $605.6K2025-12-31: $504.8K$504.8K
2021-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$504.8K-16.6%2026-03-16, From 2025-01-01
2024-12-31$605.6K+142.7%2026-03-16, From 2024-01-01
2023-12-31$249.6Kn/m2025-03-31, From 2023-01-01
2022-12-31$10.2K+111.4%2024-04-01, From 2022-01-01
2021-12-31$4.8Kn/a2023-03-31, From 2021-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
bioAffinity Technologies, Inc. (BIAF)2025-12-31$504.8K-16.6%
Absci Corp (ABSI)2025-12-31$11.74M-12.3%
Foxo Technologies Inc. (FOXO)2025-12-31$597.4K-51.6%
OmniAb, Inc. (OABI)2025-12-31$21.75M-7.8%
iSpecimen Inc. (ISPC)2025-12-31$1.73M-24.6%
OneMedNet Corp (ONMD)2025-12-31$65.0K+14.0%
MaxCyte, Inc. (MXCT)2025-12-31$4.34M+0.6%
NRC Health (NRC)2025-12-31$7.62M+26.6%
Charles River Laboratories International, Inc. (CRL)2025-12-27$403.31M+11.5%

Compare BIAF, ABSI, FOXO, OABI side by side · Screen every company in Services-Commercial Physical & Biological Research ↗